Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients

• DOI: 10.1016/j.sciaf.2022.e01343
• Publication Date: 2022-08-24T07:35:31Z
• Authors: Oluyemi Akinloye; Olatunji I. Kareem; Olayiwola A. Popoola; Titilola A. Samuel; Oluwatosin Adaramoye
• Keywords: 03 medical and health sciences; Prostate cancer; Benign prostatic hyperplasia; Blood; 0302 clinical medicine; mRNA; Science; Q; PCA3; Urine

Current reports show that most of the routinely available prostate specific antigen (PSA) derived biomarkers cancer (PCa) have failed to demonstrate sufficient sensitivity and specificity in clinical use for diagnosis prognosis PCa. Consequently, a number molecular markers including gene 3 (PCA3) are being considered use. This study was therefore designed determine levels PCA3 mRNA expression urine plasma patients assess its diagnostic characteristics Nigerian population with cancer. A total 90 participants comprising 30 each PCa, BPH apparently healthy adults as controls were enrolled into this case-control study. Blood samples collected from dispensed PaxGene RNA protecting fluid, lithium heparin bottles nuclease free bottle appropriate. Anthropometric indices obtained using standard methods, while PSA, testosterone estrogen determined enzyme linked immunosorbent assay (ELISA). The Quantitative Polymerase Chain Reaction. Comparison groups done analysis variance (ANOVA) followed by Tukey Post-Hoc test. PCa evaluated through estimation area under receiver operating characteristic (ROC) curve. 'The mean waist circumference (WC) (HC) significantly higher group (43.94 ± 2.32) compared both control (36.04 0.80) (38.50 0.94) (p < 0.05). had 0.05) tPSA (47.58 12.23) an increased (10.46 1.68) (14.89 1.37) when values [tPSA (0.67 0.27), (2.22 0.22) (1.45 0.13) mRNA]. negative correlation found exist between Plasma PCa3 estradiol (r=-0.425, p = 0.024) (r=-0.423, 0.025) group. similar trend observed mRNA, (r=-0.459, 0.014) (r=-0.407, 0.031). ROC curve shows 0.03) is sensitive marker detection subsequently mRNA. further 0.006) less least tPSA. It could be concluded there reduced elevated blood benign prostatic hyperplasia Hence, determination or valueable treatment monitoring